Literature DB >> 22184458

Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9.

Ruina Gao1, Liang Li, Cen Xie, Xingxing Diao, Dafang Zhong, Xiaoyan Chen.   

Abstract

Morinidazole [R,S-1-(2-methyl-5-nitro-1H-imidazol-1-yl)-3-morpholinopropan-2-ol] is a new 5-nitroimidazole class antimicrobial agent. The present study aimed to determine the metabolism and pharmacokinetics of morinidazole in humans and to identify the enzymes responsible for the formation of the major metabolites. Plasma and urine samples were collected before and after an intravenous drip infusion of 500 mg of racemic morinidazole. Ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry revealed 10 metabolites. Morinidazole glucuronidation, followed by renal excretion, was the major elimination pathway, accounting for 35% of the dose. The metabolic pathway displayed regioselectivities and stereoselectivities. Unexpectedly, the nitrogen atom of the morpholine ring, rather than the aliphatic hydroxyl group at the side chain, was glucuronidated to form S-morinidazole glucuronide (M8-1) and R-enantiomer glucuronide (M8-2). The plasma exposure of M8-2 was 6-fold higher than that of M8-1, accounting for 22.9 and 3.96% of the parent drug exposure, respectively. Investigation of morinidazole glucuronidation using human liver microsomes (HLMs) and 12 recombinant UDP glucuronosyltransferases (UGTs) indicated that this biotransformation was mainly catalyzed by UGT1A9. A kinetic study showed that N(+)-glucuronidation of racemic morinidazole in both HLMs and in UGT1A9 obeyed a typical Michaelis-Menten plot. The K(m) values for M8-1 and M8-2 formation by HLMs were similar (11.3 and 15.1 mM), but the V(max) values were significantly different (111 and 1660 pmol · min(-1) · mg protein(-1)). Overall, after an intravenous administration, morinidazole and its metabolites were eliminated in humans primarily via renal excretion. The major metabolites were two diastereoisomeric N(+)-glucuronides, and UGT1A9 played an important role in N(+)-glucuronidation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22184458     DOI: 10.1124/dmd.111.042689

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201).

Authors:  Xingxing Diao; Jeremy Carlier; Mingshe Zhu; Shaokun Pang; Robert Kronstrand; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Forensic Toxicol       Date:  2016-07-06       Impact factor: 4.096

2.  Hepatic Transport of 25-Hydroxyvitamin D3 Conjugates: A Mechanism of 25-Hydroxyvitamin D3 Delivery to the Intestinal Tract.

Authors:  Chunying Gao; Michael Z Liao; Lyrialle W Han; Kenneth E Thummel; Qingcheng Mao
Journal:  Drug Metab Dispos       Date:  2018-02-21       Impact factor: 3.922

3.  In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22.

Authors:  Xingxing Diao; Karl B Scheidweiler; Ariane Wohlfarth; Shaokun Pang; Robert Kronstrand; Marilyn A Huestis
Journal:  AAPS J       Date:  2016-01-25       Impact factor: 4.009

4.  Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites.

Authors:  Kan Zhong; Xiuli Li; Cen Xie; Yifan Zhang; Dafang Zhong; Xiaoyan Chen
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

5.  Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects.

Authors:  Xiaoyan Pang; Yifan Zhang; Ruina Gao; Kan Zhong; Dafang Zhong; Xiaoyan Chen
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

6.  Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.

Authors:  Michael Gerisch; Thomas Schwarz; Dieter Lang; Gabriele Rohde; Stefanie Reif; Isabelle Genvresse; Susanne Reschke; Dorina van der Mey; Camille Granvil
Journal:  Cancer Chemother Pharmacol       Date:  2017-07-11       Impact factor: 3.333

7.  Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis.

Authors:  Sabine Klein; Chandana B Herath; Robert Schierwagen; Josephine Grace; Tom Haltenhof; Frank E Uschner; Christian P Strassburg; Tilman Sauerbruch; Thomas Walther; Peter W Angus; Jonel Trebicka
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

8.  Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes.

Authors:  Xingxing Diao; Karl B Scheidweiler; Ariane Wohlfarth; Mingshe Zhu; Shaokun Pang; Marilyn A Huestis
Journal:  Forensic Toxicol       Date:  2016-03-28       Impact factor: 4.096

9.  Metabolites of alectinib in human: their identification and pharmacological activity.

Authors:  Mika Sato-Nakai; Kosuke Kawashima; Toshito Nakagawa; Yukako Tachibana; Miyuki Yoshida; Kenji Takanashi; Peter N Morcos; Martin Binder; David J Moore; Li Yu
Journal:  Heliyon       Date:  2017-07-10

10.  Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects.

Authors:  Guolan Wu; Wenling Tang; Duo Lv; Lihua Wu; Huili Zhou; Xi Yang; Yunliang Zheng; You Zhai; Jianzhong Shentu
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.